NDLI: Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs

Please wait, while we are loading the content...

Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs

Determination of Drug Binding to Plasma Proteins Using Competitive Equilibrium Binding to Dextran-Coated Charcoal

Semi-Mechanistic Pharmacodynamic Modeling for Degarelix, a Novel Gonadotropin Releasing Hormone (GnRH) Blocker

Assessment of Dosing Impact on Intra-Individual Variability in Estimation of Parameters for Basic Indirect Response Models

Potential γ-Hydroxybutyric acid (GHB) Drug Interactions Through Blood–Brain Barrier Transport Inhibition: A Pharmacokinetic Simulation-Based Evaluation

Journal of Pharmacokinetics and Pharmacodynamics : Volume 33, Issue 4, August 2006

Journal of Pharmacokinetics and Pharmacodynamics : Volume 33, Issue 3, June 2006

Journal of Pharmacokinetics and Pharmacodynamics : Volume 33, Issue 2, April 2006

Journal of Pharmacokinetics and Pharmacodynamics : Volume 33, Issue 1, February 2006

Journal of Pharmacokinetics and Pharmacodynamics : Volume 32

Journal of Pharmacokinetics and Pharmacodynamics : Volume 31

Journal of Pharmacokinetics and Pharmacodynamics : Volume 30

Journal of Pharmacokinetics and Pharmacodynamics : Volume 29

Journal of Pharmacokinetics and Pharmacodynamics : Volume 28

Journal of Pharmacokinetics and Pharmacodynamics : Volume 27

Journal of Pharmacokinetics and Pharmacodynamics : Volume 26

Journal of Pharmacokinetics and Pharmacodynamics : Volume 25

Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs

Content Provider	Springer Nature Link
Author	Gueorguieva, Ivelina Aarons, Leon Rowland, Malcolm
Copyright Year	2006
Abstract	Modelling is an important applied tool in drug discovery and development for the prediction and interpretation of drug pharmacokinetics. Preclinical information is used to decide whether a compound will be taken forwards and its pharmacokinetics investigated in human. After proceeding to human little to no use is made of these often very rich data. We suggest a method where the preclinical data are integrated into a whole body physiologically based pharmacokinetic (WBPBPK) model and this model is then used for estimating population PK parameters in human. This approach offers a continuous flow of information from preclinical to clinical studies without the need for different models or model reduction. Additionally, predictions are based upon single parameter values, but making realistic predictions involves incorporating the various sources of variability and uncertainty. Currently, WBPBPK modelling is undertaken as a two-stage process: (i) estimation (optimisation) of drug-dependent parameters by either least squares regression or maximum likelihood and (ii) accounting for the existing parameter variability and uncertainty by stochastic simulation. To address these issues a general Bayesian approach using WinBUGS for estimation of drug-dependent parameters in WBPBPK models is described. Initially applied to data in rat, this approach is further adopted for extrapolation to human, which allows retention of some parameters and updating others with the available human data. While the issues surrounding the incorporation of uncertainty and variability within prediction have been explored within WBPBPK modeling methodology they have equal application to other areas of pharmacokinetics, as well as to pharmacodynamics.
Starting Page	571
Ending Page	594
Page Count	24
File Format	PDF
ISSN	1567567X
Journal	Journal of Pharmacokinetics and Pharmacodynamics
Volume Number	33
Issue Number	5
e-ISSN	15738744
Language	English
Publisher	Kluwer Academic Publishers-Plenum Publishers
Publisher Date	2006-06-29
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	bayesian analysis population pharmacokinetics physiologically based pharmacokinetic models rat human diazepam
Content Type	Text
Resource Type	Article
Subject	Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study

Population-Based Analysis of Methadone Distribution and Metabolism Using an Age-Dependent Physiologically Based Pharmacokinetic Model

Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics

Propagation of Population Pharmacokinetic Information Using a Bayesian Approach: Comparison with Meta-Analysis

Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions (1996)

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model

Comparing models for perfluorooctanoic acid pharmacokinetics using Bayesian analysis

Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs

Similar Documents

Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study

Population-Based Analysis of Methadone Distribution and Metabolism Using an Age-Dependent Physiologically Based Pharmacokinetic Model

Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics

Propagation of Population Pharmacokinetic Information Using a Bayesian Approach: Comparison with Meta-Analysis

Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions (1996)

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model

Comparing models for perfluorooctanoic acid pharmacokinetics using Bayesian analysis

Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs